SynCardia Systems, LLC, a global leader in total artificial heart technology and a subsidiary of Picard Medical, Inc., has achieved a major milestone in its mission to revolutionize cardiac care. The China National Intellectual Property Administration (CNIPA) has officially granted the company its first patent for the next-generation total artificial heart, marking a critical step forward in the development of life-saving solutions for advanced heart failure patients.

This newly patented technology introduces a groundbreaking design that eliminates the need for external drive mechanisms by fully integrating the pumping mechanism within the artificial heart’s implanted ventricle. Known as the "Emperor" artificial heart, this innovation builds upon SynCardia’s proven platform, enhancing patient outcomes and increasing accessibility to advanced cardiac support systems.

“This notification from CNIPA underscores the global significance of our mission to advance artificial heart technology,” said Patrick NJ Schnegelsberg, CEO of SynCardia Systems. “The patent represents a pivotal component in bringing the SynCardia Total Artificial Heart and the Emperor artificial heart to patients in China, offering hope and life-saving care to those in critical need.”

SynCardia Systems is dedicated to advancing its technologies while expanding access to its artificial heart systems in new markets. The company’s flagship product, the SynCardia Total Artificial Heart (STAH), remains the only US FDA- and Health Canada-approved artificial heart and has been successfully used by more than 2,100 patients worldwide.

As part of its commitment to global health, SynCardia continues to collaborate with international regulatory bodies and partners to ensure the availability of its current and next-generation artificial hearts. With the Emperor design, the company is poised to redefine the landscape of cardiac care, providing an innovative and fully implantable solution for advanced heart failure patients worldwide.